Skip to content
TrialMatch
Sign up
Recruiting

Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease

Create a profile to match View the full record on ClinicalTrials.gov

About this study

Previous studies have shown that repetitive transcranial magnetic stimulation (rTMS) can improve cognitive function in Alzheimer's disease (AD), but studies on the improvement of sleep disorders in AD are limited. The aim of this study was to evaluate the effects of rTMS on sleep and cognition in patients with mild-to-moderate Alzheimer's disease (AD).

Condition
Alzheimer Disease
Tested
Real repetitive transcranial magnetic stimulation, Sham repetitive transcranial magnetic stimulation
Sponsor
First Affiliated Hospital of Zhejiang University

Who can join

Age
55 to 80 years
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 13

  • Minimum age: 55 years
  • Maximum age: 80 years
  • Study condition: Alzheimer Disease
  • Participant meets 2014 IWG-2 criteria for hippocampal amnestic syndrome, typical of AD, with progressive episodic memory impairment confirmed by neuropsychology.
  • Cerebrospinal fluid markers (Aβ40, Aβ42, T-tau, p-tau) consistent with AD, or AV-45 PET imaging showing significant cortical tracer retention, in line with AD pathophysiology.
  • Age range: 55-80 years.
  • No visual or hearing impairment.
  • Right-handed.
  • Han nationality.
  • Signed informed consent.
  • Reliable caregivers as information providers.
  • MMSE score: 10-27; CDR: 0.5-2 points.
  • If receiving approved AD treatment (e.g., acetylcholinesterase inhibitor or memantine), dose must be stable for ≥3 months prior to screening and unchanged unless medically necessary.

Exclusion 12

  • History of seizures or epilepsy diagnosis;
  • Stroke history;
  • Nervous system diseases causing brain dysfunction (schizophrenia, severe anxiety/depression, dementia, Huntington's, brain tumors, Parkinson's, metabolic encephalopathy, encephalitis, MS, epilepsy, brain trauma, hydrocephalus);
  • Severe liver/kidney/lung dysfunction, anemia, gastrointestinal disease, arrhythmia, recent MI;
  • Barbiturate/benzodiazepine use within 2 weeks;
  • MRI/TMS contraindications (metallic implants);
  • Systemic diseases causing cognitive impairment (hypothyroidism, folate/B12 deficiency, infections, alcohol/drug abuse);
  • Aphasia, consciousness disturbance, inability to cooperate;
  • TMS/tDCS/DBS has been processed;
  • Underlying pathology other than AD;
  • Focal brain lesions on T1/T2 images;
  • Refusal to sign informed consent.

Where

1 site, 1 recruiting

The First Affiliated Hospital of Zhejiang University

Hangzhou, Zhejiang, China

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.